These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11772261)

  • 21. Cardiovascular risk and dyslipidemia among persons living with HIV: a review.
    Maggi P; Di Biagio A; Rusconi S; Cicalini S; D'Abbraccio M; d'Ettorre G; Martinelli C; Nunnari G; Sighinolfi L; Spagnuolo V; Squillace N
    BMC Infect Dis; 2017 Aug; 17(1):551. PubMed ID: 28793863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
    Nolan D
    Drug Saf; 2005; 28(12):1069-74. PubMed ID: 16329710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.
    Martin A; Smith DE; Carr A; Ringland C; Amin J; Emery S; Hoy J; Workman C; Doong N; Freund J; Cooper DA;
    AIDS; 2004 Apr; 18(7):1029-36. PubMed ID: 15096806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-associated lipodystrophy syndrome.
    Qaqish RB; Fisher E; Rublein J; Wohl DA
    Pharmacotherapy; 2000 Jan; 20(1):13-22. PubMed ID: 10641972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial.
    Hadigan C; Corcoran C; Basgoz N; Davis B; Sax P; Grinspoon S
    JAMA; 2000 Jul; 284(4):472-7. PubMed ID: 10904511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
    Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
    AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Self-reported signs of lipodystrophy by persons living with HIV infection.
    Dreezen C; Schrooten W; de Mey I; Goebel FD; Dedes N; Florence E; Colebunders R;
    Int J STD AIDS; 2002 Jun; 13(6):393-8. PubMed ID: 12015013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical trials (studies) currently open addressing BHC, wasting and metabolic abnormalities.
    WORLD; 1999 Nov; (No 103):6. PubMed ID: 11366860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic complications of antiretroviral therapy in children.
    Leonard EG; McComsey GA
    Pediatr Infect Dis J; 2003 Jan; 22(1):77-84. PubMed ID: 12544413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Approach to the human immunodeficiency virus-infected patient with lipodystrophy.
    Brown TT
    J Clin Endocrinol Metab; 2008 Aug; 93(8):2937-45. PubMed ID: 18685115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial.
    van Wijk JP; de Koning EJ; Cabezas MC; op't Roodt J; Joven J; Rabelink TJ; Hoepelman AI
    Ann Intern Med; 2005 Sep; 143(5):337-46. PubMed ID: 16144892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
    Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
    Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On the trail of fugitive fat: the chase turns to NRTIs.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1999 Oct; 5(10):24-43. PubMed ID: 11366871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.
    Gougeon ML; Pénicaud L; Fromenty B; Leclercq P; Viard JP; Capeau J
    Antivir Ther; 2004 Apr; 9(2):161-77. PubMed ID: 15134178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wasting and lipodystrophy in patients infected with HIV: a practical approach in clinical practice.
    Fisher K
    AIDS Read; 2001 Mar; 11(3):132-3, 137-40, 147. PubMed ID: 17004351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.
    Brinkman K; Smeitink JA; Romijn JA; Reiss P
    Lancet; 1999 Sep; 354(9184):1112-5. PubMed ID: 10509516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipodystrophy despite anabolic steroids.
    O'Mahony C; Price LM; Nelson M
    Int J STD AIDS; 1998 Oct; 9(10):619. PubMed ID: 9819116
    [No Abstract]   [Full Text] [Related]  

  • 38. The HIV-associated lipodystrophy syndrome: research, results, yet more questions.
    Gharakhanian S
    AIDS; 2001 Jan; 15(2):271-3. PubMed ID: 11216938
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review.
    Hansen BR; Haugaard SB; Iversen J; Nielsen JO; Andersen O
    Scand J Infect Dis; 2004; 36(4):244-53. PubMed ID: 15198179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings.
    Finkelstein JL; Gala P; Rochford R; Glesby MJ; Mehta S
    J Int AIDS Soc; 2015; 18(1):19033. PubMed ID: 25598476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.